Rafael Holdings, Inc. Class B Common Stock
RFLRafael Holdings, Inc. Class B (RFL) is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative medical therapies. The company is involved in advancing treatments in areas such as oncology and ophthalmology, aiming to bring novel solutions to unmet medical needs through research and collaborations.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 31, 2009 | $0.02 | 2009-12-18 | 2009-12-22 |
| June 30, 2009 | $0.01 | 2009-06-19 | 2009-06-23 |
| March 31, 2009 | $0.02 | 2009-03-20 | 2009-03-24 |
| December 31, 2008 | $0.14 | 2008-12-19 | 2008-12-23 |
Dividends Summary
- Consistent Payer: Rafael Holdings, Inc. Class B Common Stock has rewarded shareholders with 4 dividend payments over the past 1 years.
- Total Returned Value: Investors who held RFL shares during this period received a total of $0.20 per share in dividend income.
- Latest Payout: The most recent dividend of $0.02/share was paid 5867 days ago, on December 31, 2009.
- Yield & Schedule: RFL currently pays dividends quarterly with an annual yield of 16.63%.
- Dividend Growth: Since 2008, the dividend payout has decreased by 85.6%, from $0.14 to $0.02.
Company News
B.O.S. Better Online Solutions reported strong Q2 2025 results with 36% revenue growth and 53% net income increase, driven primarily by defense sector demand and a robust supply chain division.
Rafael Holdings announced that CEO Bill Conkling will be stepping down, with Executive Chairman Howard Jonas assuming the CEO role. The company is focused on the development of its lead clinical candidate, Trappsol® Cyclo™, for the treatment of Niemann-Pick Disease Type C1.
Rafael Holdings has completed its merger with Cyclo Therapeutics, a biotechnology company focused on developing treatments for Niemann-Pick Disease Type C1. The combined company will focus on advancing Cyclo's lead clinical candidate, Trappsol® Cyclo™, which is currently in a Phase 3 trial for NPC1.
Rafael Holdings reported a net loss for the second quarter and first six months of fiscal year 2025, primarily due to unrealized losses on its investment in Cyclo Therapeutics. The company is focused on Cyclo's lead clinical program Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 following the planned merger with Cyclo Thera...
Rafael Holdings reported a net loss for Q2 and H1 FY2025 due to unrealized losses on its investment in Cyclo Therapeutics, which it plans to merge with. The company is focused on advancing Cyclo's lead clinical program, Trappsol® Cyclo™, for the treatment of Niemann-Pick Disease Type C1.
